Canada allows combination of Janssen’s Zytiga with ADT in to treat certain prostate cancer (mHSPC)

Johnson & Johnson’s Janssen has welcomed the news from Health Canada as it got approval to use Zytiga combined with prednisone and androgen deprivation therapy (ADT) for newly diagnosed, high-risk metastatic hormone-sensitive prostate cancer (mHSPC) who may have received up to three months of prior ADT.

The study upon which the approval has been based on, showed that the combination of Zytiga and prednisone and ADT reduced the risk of death by 38% compared to placebo plus ADT in patients with mHSPC.

Dr. Fred Saad, Chief of Urology, in a Montréal hospital, who was Université de Montreal clinical investigator, said that Zytiga provides a new first-line treatment option for high-risk metastatic hormone-sensitive prostate cancer that improves overall survival and quality of life.